How Olaparib Targets Ovarian Cancer Cells
Olaparib inhibits poly (ADP-ribose) polymerase (PARP) enzymes, primarily PARP-1 and PARP-2, which repair single-strand DNA breaks through a process called PARylation. In ovarian cancer cells, especially those with BRCA1/2 mutations or other homologous recombination deficiencies (HRD), this inhibition traps PARP on DNA, preventing repair and causing double-strand breaks during replication. These cells lack effective homologous recombination repair, leading to stalled forks, genomic instability, and cell death—a mechanism called synthetic lethality.[1][2]
High-grade serous ovarian cancers often have HRD (about 50% of cases), making them particularly vulnerable. Olaparib exploits this by selectively killing deficient cells while sparing normal ones with intact repair pathways.[3]
Clinical Impact in Ovarian Cancer Treatment
In maintenance therapy after platinum-based chemotherapy, olaparib extends progression-free survival (PFS) from 4-8 months to 19-28 months in BRCA-mutated cases, per SOLO-1 and PAOLA-1 trials. Overall response rates reach 40-60% in recurrent settings for HRD-positive tumors.[4][5] FDA approvals cover frontline maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer, often combined with bevacizumab.
Real-world data show 2-year PFS rates of 70-80% in responders, reducing recurrence risk by 65-70%.[6]
Why Ovarian Cancer Responds Better Than Other Cancers
Ovarian tumors have the highest BRCA1/2 mutation prevalence (15-20%) among solid tumors, plus broader HRD from CCNE1 amplification or other defects. This "BRCAness" phenotype predicts response, unlike in lower-HRD cancers like colorectal. Tumor microenvironment factors, like high hypoxia, amplify PARP trapping effects.[7][8]
Common Side Effects from PARP Inhibition
Patients experience anemia (20-40%, due to stressed bone marrow repair), nausea (60-75%), fatigue (60%), and thrombocytopenia (10-20%). Rare risks include myelodysplastic syndrome/leukemia (1-2%) from cumulative DNA damage in stem cells. Dose reductions occur in 20-30% of cases but rarely lead to discontinuation.[9][10]
Resistance Mechanisms and How Tumors Evade It
Resistance arises via BRCA reversion mutations (restoring HR), increased drug efflux (e.g., ABC transporters), or upregulated alternative repair like 53BP1 loss. About 40-50% of initial responders relapse within 2 years. Combination strategies, like with ATR inhibitors or immunotherapy, aim to overcome this by targeting multiple repair pathways.[11][12]
Who Makes Olaparib and Patent Status
AstraZeneca markets olaparib as Lynparza. U.S. patents cover the compound until 2028-2030 (extended by pediatric exclusivity), with challenges from generics like Dr. Reddy's. Exclusivity for certain indications lasts until 2027. Check DrugPatentWatch.com for litigation updates and expiry timelines.[13][14]
Sources
[1] https://www.nature.com/articles/nrc.2015.21 (Review on PARP inhibitors)
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1600017 (SOLO-1 trial)
[3] https://ascopubs.org/doi/10.1200/JCO.19.01564 (HRD mechanisms)
[4] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-maintenance-treatment-brca-mutated-advanced-ovarian-cancer
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1911361 (PAOLA-1)
[6] https://pubmed.ncbi.nlm.nih.gov/34864876/ (Real-world PFS)
[7] https://www.cell.com/cancer-cell/fulltext/S1535-6108(18)30528-4 (BRCAness in ovarian)
[8] https://pubmed.ncbi.nlm.nih.gov/29394945/ (Hypoxia effects)
[9] https://www.lynparza.com/ovarian-cancer (Prescribing info)
[10] https://pubmed.ncbi.nlm.nih.gov/32966229/ (Safety meta-analysis)
[11] https://www.nature.com/articles/s41573-020-0084-1 (Resistance review)
[12] https://pubmed.ncbi.nlm.nih.gov/35046611/ (Combo trials)
[13] https://www.drugpatentwatch.com/p/tradename/LYNPARZA
[14] https://www.fda.gov/drugs/development-approval-process-drugs/hematologic-malignancies-regulatory-information